Loading
Cardiac Valve Diseases and Treatments · Review
Biomedicines · July 27, 2026
Encouraging direction, but not yet definitive.
This narrative review synthesizes evidence from three randomized clinical trials evaluating oral sirolimus, prednisone, and colchicine as cost-effective systemic adjuncts to bare-metal stent implantation. The drugs demonstrated anti-inflammatory and antiproliferative effects with clinical outcomes reported as comparable to drug-eluting stents in highly select populations, but the review acknowledges insufficient evidence and calls for larger, long-term trials to establish safety, dosing, and patient selection criteria.
Narrative review of randomized clinical trials. Patients undergoing coronary bare-metal stent implantation. Intervention: Oral sirolimus (rapamycin), prednisone, and colchicine following bare-metal stent implantation. Compared with: Drug-eluting stents.
Oral sirolimus, prednisone, and colchicine demonstrate promising anti-inflammatory and antiproliferative effects Clinical outcomes comparable to DES reported in highly select population following BMS implantation Strategy proposed as feasible, cost-effective alternative where DES use restricted by cost or contraindications
Long-term safety and optimal dosing not established in this review; authors explicitly call for larger-scale, long-term trials
Clinicians in resource-limited settings may consider oral immunosuppressive or anti-inflammatory agents as a potential cost-effective alternative to drug-eluting stents in selected patients, but current evidence remains preliminary and larger prospective trials are needed before changing practice.
Narrative review of three randomized trials showing oral immunosuppressive agents achieve outcomes comparable to drug-eluting stents after bare-metal stent implantation in selected populations, but lacks head-to-head effect sizes and calls for larger confirmatory trials.
As stated by the source record.
Clinicians in resource-limited settings may consider oral immunosuppressive or anti-inflammatory agents as a potential cost-effective alternative to drug-eluting stents in selected patients, but current evidence remains preliminary and larger prospective trials are needed before changing practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Background: Coronary stenting remains the cornerstone of interventional cardiology. Drug-eluting stents (DES) have reduced restenosis compared to bare-metal stents (BMS), but their high cost and need for prolonged dual antiplatelet therapy (DAPT) limit accessibility in many regions. Recent evidence has revisited the potential role of systemic pharmacologic adjuncts—oral sirolimus (rapamycin), prednisone and colchicine—as cost-effective therapies to mitigate restenosis and adverse events following BMS implantation. Objective: This review critically evaluates the clinical and mechanistic evidence supporting the use of oral immunosuppressive or anti-inflammatory drugs following BMS implantation, with emphasis on their applicability in both resource-limited and general cardiology settings. Three randomized clinical trials comparing this strategy against DES are analyzed and discussed in this review. Conclusions: Oral sirolimus, prednisone, and colchicine demonstrate promising anti-inflammatory and antiproliferative effects that translate into clinical outcomes comparable to DES in a highly select population. Their systemic administration following BMS implantation may provide a feasible, cost-effective alternative where DES use is restricted by cost or clinical contraindications. Larger-scale, long-term trials are warranted to confirm safety, optimize dosing, and identify ideal patient populations for this “pharmacologic stent hybrid” strategy.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.